A New Path Forward for Treatment-Resistant Depression
When Standard Antidepressants Aren't Enough
SPRAVATO® (esketamine) at Mercury Mental Health
SPRAVATO® is an FDA-approved prescription medication administered under medical supervision for adults with treatment-resistant depression. If you've tried antidepressants but continue to struggle with depression, SPRAVATO® may offer a different path forward.
Insurance coverage is common, and our team will help determine eligibility and obtain prior authorization when needed.
How to start
-
Insurance benefit verification
-
Initial evaluation appointment
-
Prior authorization for Spravato, if approved and appropriate, we’ll schedule your first treatment session.
-
Month One: 2 treatment sessions weekly
-
Month Two: 1 treatment session weekly
-
Maintenance: treatment sessions occur weekly or every 2 weeks for those who receive benefit
Questions? Please email us at: hello@mercurymentalhealth.com
Disclaimer: This page is informational and not medical advice. Final eligibility and scheduling follow clinical evaluation and payer requirements.
This treatment may be a good fit for:
-
Adults who have not experienced sufficient improvement after at least two trials of different antidepressants.
-
Those who have not tolerated traditional antidepressants well, including side effects like weight gain, sexual dysfunction, or emotional and motivational blunting.
-
Those who want relief fast. SPRAVATO® (esketamine) works differently than standard antidepressants and may help some within hours to days.
Please note: Eligibility will be determined during your initial appointment.
What to expect at your Spravato in-office visit
-
Brief check-in and vitals → self-administer SPRAVATO® under supervision → quiet recovery with monitoring for 2 hours in a comfortable recliner with optional eye mask, blanket, and gentle music.
-
Please plan to arrange for a ride home.
Adverse effects
Most side effects from Spravato occur during or shortly after treatment (such as dissociation, sedation, dizziness, nausea, respiratory depression, and temporary increases in blood pressure), which is why patients are monitored in-office for at least two hours. For most patients, side effects are temporary and resolve the same day. Long-term or persistent side effects are uncommon, and we monitor for safety throughout treatment.
The
Threatment Space
For clinicians & referral partners
We accept referrals for SPRAVATO® only—you keep primary medication management.
-
We manage Spravato treatment while patients continue care with their primary psychiatric provider
-
With an ROI, we provide regular updates on response and safety
-
Refer/coordinate: hello@mercurymentalhealth.com | Fax (812) 407-2467